Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period of March 28, 2014. The company is a Delaware corporation focused on stem cell therapies. The filing reports a specific scientific development rather than routine financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the publication of a study in the peer-reviewed journal PLOS ONE. The study demonstrated that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional improvements.
Outlook, Risks, and Management Commentary
Management highlighted the positive preclinical results as a significant milestone. The filing includes a press release (Exhibit 99.01) detailing the study. No specific financial guidance, risk factors, or contingencies are detailed within the text of this specific 8-K form.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for detailed study parameters.
- Confirm the publication details in PLOS ONE to validate the peer-reviewed status of the NSI-566 study.
- Review subsequent filings for any updates on the clinical translation of these preclinical rat study results.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial health metrics.